TG Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and bringing to market innovative therapies for a range of B-cell cancers and autoimmune conditions. Among its pipeline of therapeutic agents are Ublituximab, an experimental glycoengineered monoclonal antibody targeting B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and various forms of relapsing multiple sclerosis. Also featured is Umbralisib, an orally administered inhibitor specifically designed for PI3K-delta and CK1-epsilon, which addresses CLL, marginal zone lymphoma, and follicular lymphoma.